medRxiv preprint doi: https://doi.org/10.1101/2023.11.10.23298264; this version posted November 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

1	A protocol for evaluating digital technology for monitoring sleep
2	and circadian rhythms in older people and people living with
3	dementia in the community
4	
5	Ciro della Monica ^{1,2} *, Kiran K. G. Ravindran ^{1,2} , Giuseppe Atzori ^{1,2} , Damion Lambert ^{1,2} , Thalia
6	Rodriguez-Garcia ^{1,2,3} , Sara Mahvash-Mohammadi ^{2,4} , Ullrich Bartsch ^{1,2} , Anne C. Skeldon ^{2,3} ,
7	Kevin Wells ^{2,4} , Adam Hampshire ⁵ , Ramin Nilforooshan ^{2,6} , Hana Hassanin ^{2,7,8} , the UK
8	Dementia Research Institute Care Research & Technology Research Group ² , Victoria L.
9	Revell ^{1,2} , Derk-Jan Dijk ^{1,2}
10	
11	¹ Surrey Sleep Research Centre, University of Surrey, Guildford, UK
12	² UK Dementia Research Institute Care Research & Technology Centre (CR&T) at Imperial
13	College London and the University of Surrey
14	³ School of Mathematics & Physics, University of Surrey, Guildford, UK
15	⁴ Centre for Vision, Speech and Signal Processing, University of Surrey, Guildford, UK
16	⁵ Department of Brain Sciences, Imperial College, London, UK
17	⁶ Surrey and Borders Partnership NHS Foundation Trust Surrey, Chertsey, UK
18	⁷ Surrey Clinical Research Facility, University of Surrey, Guildford, UK
19	⁸ NIHR Royal Surrey CRF, Guildford, UK.
20	
21	*Corresponding Author:
22	Email: c.dellamonica@surrey.ac.uk (CdM)
23	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 Abstract

25 Sleep and circadian rhythm disturbance are predictors of poor physical and mental health, 26 including dementia. Long-term monitoring of sleep and circadian rhythms in people living in 27 the community may have great potential for early diagnosis, monitoring of disease progression and assessing the effectiveness of interventions in dementia and other health 28 conditions. Many novel digital technology-based approaches for monitoring sleep and 29 30 circadian rhythms, aimed at both the consumer and research markets, have recently 31 become available. However, before such technology can be implemented at scale, its 32 performance and acceptability need to be evaluated and compared to established gold 33 standard methodology in relevant populations. 34 Here we describe a protocol for the evaluation of novel sleep and circadian technology in 35 cognitively intact older adults, some of whom have stable comorbidities, and in people living 36 with dementia (PLWD). In this protocol a range of technologies is tested simultaneously first 37 at-home during a one- to two-week period and subsequently in a clinical research facility in 38 which gold standard methodology for assessing sleep and circadian physiology is 39 implemented. 40 We emphasize the importance of assessing both nocturnal and diurnal sleep (naps), valid markers of circadian physiology, and that evaluation of sleep and circadian technology is 41

42 best achieved in protocols in which sleep is mildly disturbed and in populations and settings

43 that are relevant to the targeted use-case. We provide details on the design,

44 implementation, and challenges of this sleep and circadian technology evaluation protocol

45 along with examples of the datasets that have been generated in both cognitively intact

dellaMonica C_et_al_Manuscript.docx

46 older adults and PLWD. We place our protocol in the context of existing literature and
47 highlight the benefits that our methodology has over previous approaches.

48

49 Author Summary

50 Sleep and circadian (24-hour) rhythms are frequently disrupted in various physical and 51 mental health conditions including dementia. These disturbances may merely be an 52 outcome of the disease process or be drivers of disease progression. Either way, the ability 53 to monitor sleep and circadian rhythms long-term and at-home could be highly beneficial 54 for monitoring health status, early identification of decline, and implementation of interventions as well as monitoring the effectiveness of interventions. A number of new 55 56 digital health technologies are now available that could allow non-invasive, non-intrusive, 57 long-term monitoring of sleep and circadian rhythms at home. However, few of these have been evaluated against gold-standard measures in a relevant population. Here we describe 58 59 our approach to simultaneously evaluating multiple types of sleep and circadian 60 technologies against standard methodology, both at-home and in the laboratory, in a group 61 of older adults with and without dementia. We discuss the feasibility of this protocol, 62 provide examples of the data that were obtained, the data analyses and visualisations that can be applied, and explain the benefits of our approach. 63 64 Introduction 65

66 The need for technology to monitor sleep and circadian rhythms longitudinally

67 Sleep and the circadian system are important contributors to well-being and both physical

68 and mental health [1-4]. Disruptions to sleep or the circadian clock in ill health may be a

69 predictor of and/or contributor to disease progression as well having a negative impact on 70 quality of life. Much of our knowledge in this area is based on self-report, cross-sectional 71 studies or short-term laboratory studies. The capacity to unobtrusively monitor sleep-wake 72 cycles, circadian rhythms, and other health indicators over long periods of time at home 73 offers opportunities: a) to monitor disease progression and associated clinical outcomes, b) 74 for early detection of decline and implementation of appropriate action, c) to increase 75 understanding of the relationship between sleep/circadian physiology and clinical 76 symptoms/intervention/recovery/response. In addition, longitudinal monitoring of sleep 77 and the circadian system within an individual may facilitate the development of personalised interventions to improve clinical symptoms and quality of life. 78 79 The timing, duration and quality of sleep is regulated by an interaction of two well-80 characterised biological processes: circadian rhythmicity, and a sleep-wake dependent 81 process which is often referred to as sleep homeostasis [5-8]. The sleep homeostat 82 monitors time awake whereas the circadian system drives 24-hour rhythms in nearly all 83 aspects of our physiology and behaviour. The master circadian clock, the suprachiasmatic nuclei (SCN) of the hypothalamus is synchronised to the 24-hour day by environmental light 84 85 (e.g., [3, 9]); in addition, environmental light can also modify our levels of alertness, mood, 86 and performance [10]. 87 People living with dementia (PLWD) and their caregivers are examples of populations that may benefit from monitoring of sleep and circadian rhythms over long periods of time. 88

89 Disturbances of sleep and circadian rhythms are highly prevalent in dementia and include

night-time awakening and wandering, long naps during the daytime, and early or late sleep

91 timing [11-14]. Sleep timing disturbances may vary across various dementias such as fronto-

92 temporal dementia (FTD) and Alzheimer's disease [15]. In addition, sleep disorders are

93	prevalent in dementia, particularly obstructive sleep apnoea and REM sleep behaviour
94	disorder which are risk factors for dementia and neurodegeneration and contribute to
95	cognitive decline [16-18]. These disruptions not only have consequences for health and
96	social care costs but also affect the quality of life of both the PLWD and their care giver (e.g.,
97	[19-22]) and are a major contributing factor to the PLWD being moved into care homes
98	(e.g., [23-25]). These sleep and circadian disturbances may be a consequence of the disease
99	process and, as such, be an indicator of disease progression (e.g., [26]). Alternatively, or
100	additionally, sleep disturbances may actually drive disease progression and thus be a target
101	for intervention to improve the quality of life of both PLWD and their carers. Furthermore,
102	night-to-night variation in aspects of sleep and sleep continuity in particular have been
103	shown to predict day-to-day variation in symptoms in dementia [27]. Longitudinal
104	monitoring of sleep and circadian physiology will benefit our understanding of their
105	interaction with health outcomes in dementia.
106	

107 Gold standard assessments of sleep and circadian rhythms: advantages and disadvantages 108 We can measure sleep in many different ways from simple self-report (e.g., sleep diaries), to 109 increasing complexity at the behavioural (e.g. bed occupancy), and physiological (e.g., EEG, 110 cardiovascular) level. In addition, the classification of sleep can be made at the simple sleep 111 vs wake distinction to the more detailed macrostructure of the different stages of non-rapid 112 eye movement sleep (NREM) stages N1 to N3 and REM sleep, and finally to the 113 microstructure of the electroencephalogram (EEG) signal, as reflected in power spectral 114 density or other EEG measures. From these different levels of measurements we can derive 115 a range of parameters to describe sleep from self-reported sleep quality to the timing of 116 sleep within the 24-h day, total sleep time (TST), sleep onset latency (SOL), wake after sleep

onset (WASO), sleep efficiency (SE), spectral power of different EEG frequency bands, and
individual EEG events such as slow waves and sleep spindles as well as their phase
relationships (e.g., [2]).

120 The gold standard method of assessing sleep is laboratory-based polysomnography 121 (PSG) which is performed in accordance with guidelines of the American Academy of Sleep 122 Medicine [28]. PSG is a comprehensive overnight physiological assessment including EEG, 123 electrooculogram (EOG), electromyogram (EMG), electrocardiogram (ECG), oxygen 124 saturation (SpO2), respiration effort and airflow, limb movement (EMG), body position, and 125 video recording. The recordings can then be scored to provide a detailed picture of sleep 126 structure and physiology, including the presence of any clinical sleep disorders such as sleep 127 apnoea where, for example, the apnoea-hypopnea index (AHI) from a single night can be 128 used to determine disease presence and severity. In addition, periodic limb movements can 129 be measured to assess for sleep-related limb movement disorder.

130 To understand the contribution of the circadian system to health and disease it is 131 necessary to be able to characterise its properties which includes: the phase (timing), 132 amplitude (strength), and period (time taken for one complete cycle) of the rhythms. 133 Traditionally, assessment of phase and amplitude has been achieved by acquiring time 134 series data of gold standard measures (e.g., melatonin, cortisol, core body temperature) in 135 highly controlled laboratory conditions (i.e., dim light, continual wakefulness, controlled posture, controlled calorie intake) [29]. More recent approaches utilise machine learning or 136 137 mathematical models to extract features from only a few samples of high dimensional data 138 e.g., transcriptomics, metabolomics, or longitudinal simultaneous recordings of light 139 exposure, activity, and physiology [29]. However, many of these approaches have yet to be

dellaMonica C_et_al_Manuscript.docx

tested and validated in different populations or under different sleep/wake, light/darkschedules.

142 These gold standard approaches can provide a detailed assessment of an individual's 143 sleep and the phase/amplitude/period of their circadian system. However, these 144 assessments: a) have high associated cost due to the requirement for participants to be 145 supervised in a laboratory environment by appropriately skilled staff, b) impose a high level of burden on participants due to amount of equipment that needs to be worn and needing 146 147 to travel away from home to a laboratory setting, c) can be invasive if blood samples are 148 collected, d) require technical analysis skills e.g., for scoring the PSG recording, and e) 149 unrepresentative of normal individual sleep patterns due to first night effects and novel 150 controlled surroundings. Moreover, a single PSG recording and single melatonin profile in 151 the laboratory only provides a snapshot of an individual's sleep/circadian physiology and 152 behaviour. Whilst these gold-standard approaches are essential for diagnoses or research 153 studies they do not provide measures of ecological validity within an individual's home over 154 an extended period of time.

155

156 Technology for monitoring sleep and circadian rhythms at home: current approaches 157 New digital health technology to monitor sleep/circadian behaviour and physiology at home 158 is constantly emerging on the consumer and research markets. Consumer monitoring devices are designed to appeal to the general public in terms of cost, appearance and the 159 160 type or level of information that they provide. These devices can potentially provide 161 behavioural level data, including bed occupancy and activity, as well as more detailed 162 physiological signals from which sleep stage, heart rate and breathing rate can be provided. 163 However, as these are consumer rather than medical devices, no particular level of

164 quantitative performance is mandated or guaranteed. Nonetheless, the ability to cost-165 effectively monitor sleep and circadian rhythms in an individual's own home offers several 166 advantages. Firstly, the assessments are made in a natural environment which allow the 167 influence of daily activities/behaviours and local environmental factors, including light and 168 temperature, on sleep and circadian rhythms to be assessed. In fact, many devices also 169 measure environmental variables including light, noise, and air quality. Secondly, 170 assessments can be made longitudinally so it is possible to determine how sleep/circadian 171 rhythms vary over time and investigate how these longitudinal variations associate with 172 changing behaviours or symptoms. Finally, the capacity to monitor sleep within a home environment may be beneficial for those suffering from sleep disorders (e.g., sleep apnoea) 173 174 where the technology may assist with diagnosis, clinical monitoring, and/or the delivery of, 175 and monitoring the efficacy of interventions.

Longitudinal assessments of circadian rhythms in the field, to date, have taken three approaches: 1) measuring rest activity patterns with wrist-worn actigraphy in conjunction with sleep diary, and using sleep timing as a proxy for the timing of the clock, 2) assessment of circadian phase through sample collection and measurement of melatonin or its metabolites at defined intervals, 3) combining light and activity measurements with mathematical models to predict circadian phase [29].

Actigraphy records limb movement activity (accelerometery) and then uses a proprietary algorithm to process this movement data to estimate whether an individual is awake or asleep for each 60 second epoch, and subsequently derive sleep measures including TST, SOL and WASO. In addition, non-parametric analysis can be conducted to determine a range of related variables: inter-daily stability (IS), a measure of day-to-day consistency of activity patterns, intra-daily variability (IV), a measure of how much activity

188 varies within a 24-hour period, 10 h of highest activity (M10), 5 h of lowest activity (L5), and 189 relative amplitude (M10: L5). However, the use of the timing of sleep/rest periods as an 190 estimate for circadian phase is not advisable [3]. The relationship between the circadian 191 clock, as indexed by melatonin, and sleep timing varies in both healthy individuals [30] but 192 also in different mental health conditions [3]. Consequently, sleep/rest timing is not a 193 reliable indicator of the timing of the internal clock. The phase relationship between sleep 194 and circadian rhythms are relevant, such that it for example predicts whether or not late 195 sleep timing (eveningness) associates with depressive symptoms [4]. 196 Field assessments of the gold standard marker of circadian phase, i.e., melatonin 197 profiles, are challenged by the fact that melatonin is sensitive to exogenous factors including 198 environmental light and posture such that participants need to follow a controlled protocol. 199 Collection of saliva samples, under dim light whilst seated, at 30 min intervals in the 3 – 4 200 hours before habitual bedtime allows the dim light melatonin onset (DLMO) to be 201 determined as a marker of circadian phase. Implementation of technology, including 202 containers that track when salivettes are removed for sampling, have allowed the 203 development of home protocols that have been validated, in a within-subject design, 204 against DLMO collected in the laboratory [31]. An alternative approach that is less 205 restrictive for participants is 48-hour urinary collections to measure the urinary metabolite 206 of melatonin, 6-sulphatoxy-melatonin (aMT6s). This methodology has been used 207 successfully in both blind individuals and those living with schizophrenia, who frequently 208 suffer circadian and sleep disruption, to track circadian phase over several weeks (e.g., [32-209 34]). It should be noted that this approach may cause burden to participants and, as the 210 circadian parameters are computed from a rhythm derived from samples collected over 4 – 211 8-hour bins, the markers may not have sufficient resolution to detect small but relevant

changes in circadian phase. More recently, statistical and mathematical models for the
interaction between the circadian system, sleep homeostat and environmental light
exposure approaches have been successfully applied to wearable data to predict circadian
phase [35-37].

216

217 Evaluating technology: the issues

The main issues with novel technology are: 1) lack of evaluation against gold standard measures such that the device output cannot be verified, 2) consumer device hardware and algorithms are constantly being updated which means that any evaluation that has been performed may be rapidly out of date, 3) if evaluation studies are performed then they are typically in young, healthy individuals for a habitual time-in-bed period where sleep

223 efficiency is high and where rest/activity rhythms are robust and regular.

224 These issues of evaluation studies means that the device performance may not 225 translate to situations of disturbed sleep/circadian rhythms or in clinical/older populations 226 who may benefit from long-term use of the devices. For example, sleep undergoes well-227 characterised changes with age, but also in dementia, at both the macro- and 228 microstructure level. These macro changes include changes in sleep timing, shortened or 229 extended nocturnal sleep duration/time in bed, increased number of nocturnal awakenings 230 and time spent awake during the night, decreased slow wave and REM sleep, and increased 231 frequency of daytime naps (reviewed in [38]). At the microarchitecture level, with age and 232 in dementia there are reductions in slow wave activity (SWA) in NREM sleep, particularly in 233 the prefrontal cortex and during the first NREM cycle of the sleep episode, as well as a 234 decreasing number of sleep spindles and reductions in REM sleep (reviewed in [39-41]). 235 This alteration in both the sleep signal and sleep continuity with age and in dementia implies

that sleep monitoring devices that perform well in young people may not do so well in older
people or in people living with dementia. Nevertheless, there is a lack of evaluation studies
in particular in PLWD [42]. For example, a recent systematic review of the validity of noninvasive sleep-measuring devices aimed at assessing their future utility in dementia, was not
able to identify any studies in people with mild cognitive impairment or Alzheimer's Disease
[43].

In addition to changes in sleep, aging is associated with changes in the circadian system in terms of its timing, amplitude, and relationship with sleep (e.g., [44]) as well as changes in light exposure, crucial for stability and robustness of the clock, due to changes in photic sensitivity (e.g., [45]) and the lived light environment (e.g., [46]). As such, circadian technologies may not perform as well in older individuals.

247 The 'International Biomarkers Workshop on Wearables in Sleep and Circadian 248 Science' held at the 2018 SLEEP Meeting of the Associated Professional Sleep Societies 249 identified that the main limitation of large-scale use of novel sleep and circadian wearables 250 is the lack of validation against gold-standard measures [47]. The workshop formulated 251 guidelines for validation and confirmed that: PSG is the only valid reference for TST and 252 sleep staging; PSG sleep records should be scored using current AASM guidelines; PSG sleep 253 records should be double scored to minimise bias. Devices differ in the level at which they 254 classify sleep-wake, from binary (sleep or wake) to four stages (wake (W), REM, light sleep 255 (LS), deep sleep (DS)) to full AASM (W, stage 1 NREM (N1), stage 2 NREM (N2), stage 3 256 NREM (N3), REM) scoring. The ability of a device to over or underestimate sleep and wake 257 will depend on its sensitivity (ability to correctly classify sleep epochs), specificity (ability to 258 correctly classify wake epochs), and accuracy (proportion of all epochs correctly detected) 259 (reviewed in [47, 48]). These factors will depend on the physiological variables and

classification system used to determine sleep and wake. For example, according to
traditional performance measures, actigraphy tends to have high sensitivity and accuracy
but low specificity [49]. Despite this, actigraphy is considered a valuable tool for long-term
monitoring of rest/activity patterns in clinical populations [50].

Although it is crucial to evaluate the performance of a device against gold-standard measures, perhaps even more important is to assess its performance longitudinally in the

266 real world where it will be used in both older adults and PLWD. Simultaneously, to increase

267 our understanding of sleep and circadian rhythms in the real-world and their interaction

268 with disease processes, it is important to monitor relevant environmental variables that may

269 impact sleep or the circadian system, in particular environmental light which is critical for

synchronising the circadian system (e.g., [9]) as well as modifying our levels of alertness,

271 mood, and performance. In addition to assessing performance, it is also critical to

272 determine that the device is cost-effective and scalable, and to assess the acceptability of

273 novel sleep/circadian monitoring devices in the end-user group. This will include assessing

274 comfort, burden, obtrusiveness, and how easy the device is to use.

275 Here we describe our approach to evaluating novel wearable and contactless sleep, 276 circadian and environmental monitoring technology in community-dwelling adults both at 277 home and in the laboratory using multiple devices simultaneously against accepted 278 standard measures. We use this approach in cognitively intact older adults as well as PLWD and their caregivers. Here, we provide some examples of the results from cognitively intact 279 280 adults and PLWD. Whilst our protocol focuses on technology that can be used in PLWD for 281 long-term monitoring at home, this approach could be applied to many technologies and 282 populations.

283

284 Materials & Methods

299

285	Our approach was to first conduct a study in cognitively intact older adults to assess the		
286	performance and acceptability of a range of devices before utilising our initial findings to		
287	design a feasibility protocol to implement selected technology in PLWD and their caregivers.		
288	Both studies used the same approach of multiple days recording at-home followed by an in-		
289	laboratory, residential overnight session. The study in cognitively intact adults is completed,		
290	and some of the results have been published [51, 52] and the study in PLWD and their		
291	caregivers is ongoing.		
292			
293	Study Design		
294	Ethical approval		
295	The study in cognitively intact older adults received a favourable opinion from the University		
296	of Surrey Ethics Committee, and the study in PLWD and their caregivers from an NHS ethics		
297	committee (22/LO/0694). The protocols are conducted in accordance with the Declaration		
298	of Helpinki and guided by the principles of Cood Clinical Practice, Written informed concent		
	or Heisinki and guided by the principles of Good Clinical Practice. Written informed consent		

300 compensated for their time and inconvenience. Within the participant information sheet, it

is obtained from participants before any procedures are performed. All participants are

301 is clearly stated that all personal data is handled in accordance with the general data

302 protection regulations (GDPR) and the UK Data Protection Act 2018. In addition, it is

303 explained that anonymised non-personal data may be transferred to the manufacturers of

304 the devices being tested if they need to process the data. The manufacturer can only access

anonymised data that details the serial number of the device, the date of recording, and the

306 signals recorded on that specific date. The manufacturers may use this anonymised data in

307 their continual assessments of the performance of their device.

308 Participants

309 For an evaluation study, the study population selected must ensure that the findings are 310 relevant to the use case. For our initial protocol in cognitively intact older adults, the 311 eligibility criteria for participation in the protocol were designed to maximize the plausibility 312 of relevance for the PLWD population. As such, the target population consisted of cognitively intact, independently living, non-smoking, men and women aged between 65 -313 85 years. Participants had to consume \leq 28 units of alcohol per week and were current non-314 315 smokers. Those with stable controlled medical conditions were included to ensure a 316 representative heterogeneous population for this age range. This approach is in contrast to 317 the stringent criteria, in relation to health conditions and medication, applied for most 318 clinical trials. 319 For our protocol in PLWD and their caregivers, the inclusion/exclusion criteria for 320 PLWD include: age range of 50 – 85 years, a confirmed diagnosis of prodromal or mild 321 Alzheimer's disease, an S-MMSE (Standardised Mini Mental State Examination, [53]) score > 322 23, living in the community and, if taking medication for dementia, being on a stable dose 323 for three months prior to recruitment. Individuals who have an unstable mental state, 324 severe sensory impairment, active suicidal ideation, or being treated for terminal illness are 325 not included. PLWD can participate in the study by themselves, or their carer/family 326 support/friend may also enrol as a 'study partner' participant. These study partners must 327 be > 18 years, have an S-MMSE score > 27, and must have known the PLWD for at least six 328 months and be able to support them in their participation. Study partners complete the 329 same procedures as the PLWD.

Cognitively intact older adults were recruited via our Clinical Research Facility
 database where potential participants have registered and consented to be contacted about

332 ongoing research. PLWD and their study partners are recruited in collaboration with local 333 NHS trusts via memory services. All participants undergo an initial telephone interview and 334 subsequent in-person screening visit to determine their eligibility to take part in the study. 335 At the screening visit for cognitively intact older adults, following informed consent, 336 participants completed a range of assessments including measurement of height, weight 337 and vital signs (body temperature, heart rate, respiration rate and blood pressure), self-338 reported medical history, and completion of baseline guestionnaires: Epworth Sleepiness 339 Scale (ESS) [54] (> 10 indicates excessive daytime sleepiness), Pittsburgh Sleep Quality Index 340 (PSQI) [55] (> 5 indicates a sleep disorder), Activities of Daily Living Questionnaire (ADL) [56] 341 and International Consultation on Incontinence Questionnaire – Urinary Incontinence (ICIQ-342 UI) [57].

343 At the screening visit for PLWD (and study partners, when applicable), and following 344 informed consent, the participants complete standard assessment tools which are 345 frequently used in this population (i.e. sMMSE [53]) Hospital Anxiety and Depression Scale 346 (HADS) [58], quality of life in Alzheimer's Disease (QoL-AD) [59] as well as the PSQI [55], and 347 medical history questionnaire. In addition, vital signs are recorded as well as height, weight, 348 and BMI. PLWD and their study partners also complete additional questionnaires either at 349 this visit or during their overnight sessions: ESS, ADL, ICIQ, National adult reading test 350 (NART) [60], Berlin questionnaire to assess for sleep apnoea [61], Horne-Ostberg questionnaire [62] to assess time of day preference, and their education level is 351 352 documented. For all participants, their general practitioner is informed of their 353 participation.

354

355

356 Technology evaluated

- 357 Within our protocol we have categorised the technology according to how it is used or what
- it is monitoring: a) wearable devices that are placed on the body (e.g., wrist, head), b)
- nearable/contactless devices that are placed near the individual (e.g., bedside or under the
- 360 mattress) to detect physiological or behavioural signals, c) environmental monitoring
- 361 devices (e.g., light, temperature), d) use-able devices that the participant interacts with
- 362 (e.g., electronic tablet for cognitive testing), e) video monitoring that provides information
- about the individual and the environment.
- 364 The technology assessed in the current study was selected on the basis of: a)
- 365 previous evaluation studies, b) inclusion in comparable studies, c) regulatory status, d) cost,
- e) potential acceptability to PLWD. We included both research grade and consumer
- 367 directed devices. The number of devices tested simultaneously took account of potential
- 368 burden on participants and ensured that adequate signals could still be obtained when
- 369 multiple devices were worn (appropriately positioned). Cognitively intact participants wore
- 370 no more than four wrist devices (two per arm) at any one time whereas in PLWD no more
- than two were worn. The technology used in each protocol is shown in Table 1.

372

373 Study Protocol

- 374 These studies are designed to assess the performance and acceptability of a range of
- devices simultaneously, firstly longitudinally at-home (7 14 days) with actiwatch/sleep
- diaries as a reference point and then in an overnight laboratory session with concurrent
- 377 gold standard video-PSG. The AASM recommends that actigraphy is always accompanied by
- 378 completion of sleep diaries to allow optimal interpretation of the actigraphic data [63] and

- that data is collected for a minimum of 72 hours to 14 days [50]. The concept of the study is
- 380 shown in Figure 1 and a schematic diagram of the protocol is shown in Figure 2.
- 381
- 382



383

- **Figure 1.** Overview of the concept of the protocol and categories of the devices included,
- the data and application domain, and the study design.



388 Figure 2. Schematic diagram of the protocol design. The people symbol indicates when the 389 telephone pre-screening assessment was conducted. The clipboard symbol indicates 390 completion of questionnaires, the heart symbol when vital signs were measured, and the 391 battery symbol indicates when participants were trained to use the technology. Grey bars 392 indicate sleep periods and white bars indicate wake periods. The symbol of a hand using an 393 electronic tablet indicates completion of the cognitive test battery, and the questionnaire is 394 completion of the sleep diary. The pink horizontal lines indicate when an EEG device was 395 used at home to measure sleep physiology. The black horizontal line indicates the use of 396 wearables and nearables throughout the at-home period.

397

398 Longitudinal monitoring at-home - Participants are provided with a range of technology to 399 use in their home to monitor their sleep/wake patterns and environmental light exposure 400 (see Table 1 for list of devices and variables measured). The technology is either installed by 401 the participants themselves or researchers may go to the participants' homes to assist 402 them. The wrist-worn/collarbone-worn devices are worn continually and participants are 403 requested to complete a log whenever they remove them to record times and reason for

404	removal. The EEG wearables are only used for one or two nights and the nearables are left
405	in situ throughout. Participants are requested to complete a modified version of the
406	Consensus Sleep Diary-M [64] (electronically or on paper) on a daily basis to record
407	subjective information about their sleep patterns, sleep quality, daytime napping as well as
408	alcohol and caffeine consumption. In addition to the standard questions, participants are
409	asked to provide further details about their daytime naps (what time, duration, where and
410	why they napped) and nocturnal awakenings (for each awakening, what time they awoke,
411	how long it took to fall asleep, if they left the bed, and if so, what time). Participants are
412	requested to complete cognitive assessments one to two hours after waking each day on an
413	electronic tablet.
414	
415	
416	
417	
418	
419	
420	
421	
422	
423	
424	
425	
426	
427	

428 **Table 1.** Commercially available and research-grade devices used in the study protocols.

Location	At home/in Lab	Study – Cognitively intact	Study – PLWD & study partner
		Wearal	bles
Wrist	At home & in Lab	Actiwatch Spectrum (Philips Respironics, US):	Withings ScanWatch (Withings, France):
		activity; sleep estimates; white, red, green, and blue	activity; sleep estimates, heart rate.
		light.	AX3 or AX6 (Axivity, UK):
		Withings Steel watch (Withings, France): activity;	activity, white light.
		sleep estimates, heart rate.	
		AX3 (Axivity, UK): activity, white light.	
		Apple watch (Apple, US): activity; sleep estimates,	
		neart rate.	
	In Lab only	E4 (Empatica, Italy): activity; wrist temperature; heart rate.	
Head	At home & in Lab	Dreem Headband 2 (Dreem, France):	Dreem Headband 2 (Dreem, France):
		EEG sleep, position, activity.	EEG sleep, position, activity.
	In Lab only	Marvels ear-EEG sensor prototype developed by	Marvels ear-EEG sensor prototype developed by Imperial College (London, UK)
		Imperial College (London, UK)	Somnomedics Home Sleep Test (SOMNOmedics GmbHTM, Germany): EEG sleep.
		Nearab	oles
Under	At home & in Lab	Withings Sleep Mattress Analyser (Withings,	Withings Sleep Mattress Analyser (Withings, France): sleep, breathing rate, heart
mattress		France): sleep, breathing rate, heart rate, activity,	rate, activity, bed occupancy.
		bed occupancy.	
		EMFIT QS (EMFIT Limited, Finland):	
		sleep, breathing rate, heart rate, activity, bed	
	In Lab ank	occupancy.	N A
	In Lab only	N:A.	
Nightstand	At home & in Lab	N.A.	Somnoty (VitalThings, Norway): sleep, breathing rate, bed occupancy.
	In Lab only	Somnofy (VitalThings, Norway):	Tiresias networked radar system prototype (Imperial College, London, UK) [65]: sleep,
		sleep, breathing rate, bed occupancy.	breathing rate, bed occupancy.
		Tiresias networked radar system prototype	
		(Imperial College, London, UK) [65]: sleep, breathing	
		rate, bed occupancy.	na u ta l
Onoworn	At home & in Lah	HORO (Tempson LIK):	HORO (Tompson LIK):
at level of	At nome & in Lub	white light temperature	white light temperature
collarbone		winte light, temperature.	white light, temperature.
when			
awake &			
one hung			
in living	In Lab only	N.A.	N.A.
space			
		Use-ab	les
N.A.	At home & in Lab	Electronic tablet with Cognitron and sleep diary.	Electronic tablet with Cognitron and sleep diary.
	In Lab only	N.A.	N.A.
		Vide	0
Sleep Lab	At home & in Lab	N.A.	N.A.
	In Lab only	Somnomedics video camera (SOMNOmedics GmbHTM, Germany).	Somnomedics video camera (SOMNOmedics GmbHTM, Germany).

429

438

430 Overnight laboratory session – The session is ~24 hours in duration and participants are 431 required to arrive in the afternoon and remain at the Research Centre, which hosts the 432 UKDRI clinical research facility at Surrey, until the following day. Upon arrival, participants' 433 vital signs are measured, and continued eligibility assessed. The devices that have been used 434 at home are downloaded, reset, and provided back to the participants with any additional 435 devices only used in the laboratory. During their stay, participants also have assessments of 436 their gait and postural stability made using video and radar technology. During the laboratory session, participants have an indwelling cannula sited for 437

collection of regular blood samples at 3-hourly intervals (including overnight) for 24 hours to

439 assess time of day variation in biomarkers. The samples are processed and are analysed for 440 levels of melatonin, as a gold-standard marker of the circadian clock, as well as biomarkers 441 of dementia e.g., neurofilament light (NfL), phosphorylated tau (p-tau), amyloid-beta (Aβ40, 442 Aβ42 (e.g., [66-68]). In addition, participants collect urine for 24 hours in four-hourly 443 intervals (eight hours overnight) for measurement of aMT6s. 444 Following dinner, participants are equipped with all the electrodes and sensors required for 445 a clinical video-polysomnographic (PSG) recording using AASM compliant equipment and 446 montage. The PSG equipment is the Somnomedics SomnoHD system with Domino software 447 (v 3.0.0.6, sampled at 256 Hz (SOMNOmedics GmbHTM, Germany) and we use an American 448 Academy of Sleep Medicine (AASM) standard adult montage. Participants can also have a wearable EEG device fitted for concurrent EEG recording and contactless sensors are 449 450 positioned for overnight recordings. Prior to the start of the PSG recording, participants are 451 asked to lie on the bed in different supine poses (prone, supine, right, left, seated) and 452 recordings are made with video and radar technology to assess the ability of the radar 453 technology to assess physiology in different poses. 454 The protocol takes advantage of the 'first night effect' and an extended period in bed to create a model for mildly disturbed sleep [69]. Participants are required to be in bed for 455 456 a 10 h recording period that is determined on the basis of their habitual time in bed period 457 (HTiBP). For example, for HTiBP < 8 h, the recording period starts one hour earlier than 458 habitual bedtime; for HTiBP > 10 h, the recording starts at habitual bedtime. For those with 459 8 h \leq HTiBP \leq 10 h the recording start time is determined as: Habitual Bedtime – [0.5*(10-460 HTiBP)]. This extended period in bed is used to ensure that the recordings include periods

461 of quiet, recumbent wake to determine if the devices can distinguish quiet wake from sleep.

462 Participants select their own lights off/on times and around these times are permitted to

463	conduct quiet, sedentary activities e.g., watching movies, reading. Overnight recordings are
464	performed in individual, environmentally controlled bedrooms or in our bespoke bedroom
465	facility that has double occupancy or adjacent room access for PLWD and their study
466	partners.
467	Upon awakening, participants are requested to complete their sleep diary and cognitive test
468	battery as well as a questionnaire about device acceptability. The questionnaire asks
469	participants to rate comfort (1 – very uncomfortable to 7 – very comfortable), ease of use (1
470	– very difficult to 7 – very ease), and to record any problems. Prior to discharge, vital signs
471	are taken and for cognitively intact older adults the S-MMSE was administered.
472	

473 Device and data management

- 474 The flow of data acquisition and data management is shown in Figure 3.
- 475



476

477 **Figure 3.** Overview of data acquisition and data management.

- 479 Device allocation Eligible participants are enrolled into the study and have a set of devices
- 480 allocated to them. All devices and systems have unique identifiers, with a one-to-one
- 481 allocation of: a) device code to participant for wearable/contactless devices used at home or

482	in the lab and b) device to location to participant for devices installed in the laboratory (e.g.,
483	floor sensor data is recorded for a specific lab room, and the room is allocated to the
484	participant). All devices are mapped to an operation schedule which means that data are
485	collected during each 24-hour period from 12 noon to 12 noon the following day unless the
486	device has continuous recording.
487	
488	Device set-up and synchronisation - To be able to directly compare the performance of
489	different devices it is essential that they are time synchronised. All network device clocks
490	are synchronised to a Network Time Protocol (NTP) server. Commercial standalone systems
491	are synchronised through the respective software applications used to set up the device
492	recordings.
493	
494	Data acquisition - The devices used are either battery powered logging devices or are
495	directly connected to power and either store data locally or are wi-fi enabled and transmit
496	data to the secure cloud servers of the manufacturers. Participants are provided with an
497	independent Wi-Fi 4G gateway for device connection.
498	Upon arrival at the laboratory, all devices are collected from participants for: a)
499	download of data and confirmation of power levels for battery powered devices, b)
500	reconfiguration of connected devices to connect to local Wi-Fi connections. Devices to be
501	used during the laboratory session are returned to the participants.
502	At the end of the lab session all logging devices are connected to the relevant secure
503	system and source data files extracted and moved to a location based on the participant,
504	day(s) and device for that data. For the online server-based systems, these are

synchronised, and data is then extracted and placed into the relevant source data filesystem.

507

- 508 Data mapping and file name convention All data recorded as a source file, or in a source
- 509 system is mapped to a named file and location based on study specific parameters e.g.,
- 510 Study Name (required), Device code (required), Test/Data/Measure (Optional), Participant
- 511 or group (required) Visit (required) Study day/night (required). Access to this Research Data
- 512 Store (RDS) is strictly controlled in accordance with Information Governance procedures for
- 513 the specific use of the study protocol owners for analysis.
- 514

515 Data processing and analysis

516 To evaluate the accuracy and reliability of the focus technology (devices being evaluated) in

517 measuring sleep, we compare it to a standard reference technology. For the at-home

518 recordings, the comparative standard measure against which all other technologies are

519 evaluated is the combination of the Actiwatch-spectrum (AWS) and Consensus Sleep Diary

520 (cognitively intact adults) or AX3 and Consensus Sleep Diary (PLWD and study partners). For

521 the in-laboratory session, the PSG is considered the gold-standard measure [28, 50, 70] for

- all participants. The PSG recordings are scored in 30 second epochs (in accordance with
- 523 AASM guidelines) by two independent scorers and a consensus hypnogram is generated.
- 524 AHI is determined using the AASM criteria for scoring apnea/hypopneas where there is \geq 3%

525 drop in oxygen saturation and/or an arousal.

526 The focus technology is evaluated against the standard reference technology (AWS + 527 sleep diary or PSG) for its ability to estimate sleep summary measures (e.g., TST, SOL). In 528 addition, in the laboratory, the focus technology is assessed for its epoch-by-epoch (EBE)

- 529 concordance with the PSG hypnogram. Sleep summary measures are obtained from
- 530 processing data using local individual proprietary software for battery logging devices or via
- raw signals being uploaded to a cloud-based server for scoring by a proprietary machine-
- 532 learning based algorithm. Our approach to data analysis is depicted in Figure 4.
- 533



- 534
- 535 Figure 4. Overview of process for evaluating consumer-grade technology against standard
- 536 device.
- 537
- 538

539 Sleep summary measures

540	The sleep summary measures can be grouped into two categories: 1) sleep/wake measures
541	e.g., TST, SOL, WASO, and SE, and 2) sleep stage duration measures. The sleep stage
542	duration measures vary depending on the level at which the focus device classifies sleep-
543	wake i.e., binary, four stages or full AASM. The interval over which the sleep summary
544	measures are calculated (analysis period) is either automatically set by the device algorithm
545	or can be manually set using either the sleep diary reported times of attempted sleep and
546	final awakening (standard for at-home recordings) or the lights off period or total recording
547	period (standard for in-laboratory recording) [28, 50]. The analysis period chosen can have
548	a substantial impact on the summary measures calculated and the performance of the
549	device when compared to home/laboratory standards [51].
550	All of the focus technologies generate summary measures automatically using the
551	device algorithm determined analysis period. The primary analysis is performed using these
552	automatic summary measure estimates. However, for completeness, the summary
553	measures can also be manually calculated.
554	A number of data visualisations (scatter plots, box plots, QQ plots, etc.) are
555	performed to check the distribution of the data and for the presence of outliers. Further
556	statistical tests are performed to check the normality of the data. For the agreement
557	estimation, Bland-Altman analysis is performed and bias, limits of agreement and minimum
558	detectable change are estimated. Other metrics that can be computed include for example
559	Pearson's correlation, consistency intraclass class correlation (ICC), effect size (Cohen's D)
560	and mean absolute percentage error (MAPE) [71, 72]. To rank the devices, the agreement
561	matrices containing the sleep measure accuracy metrics are created.

562

563 Epoch-by-epoch (EBE) concordance

564 At-home recordings: the resolution of the focus technology's hypnogram is reduced to binary sleep/wake classification to match the AWS which is used as the comparative 565 566 standard measure. The analysis window is set between 18:00 h to 12:00 h and all common 567 periods of sleep/wake timeseries are evaluated. 568 In-laboratory recordings: the PSG hypnogram resolution is reduced to match the levels of 569 sleep stage output by the device (e.g., N1+N2 = light sleep (LS) and N3 = deep sleep (DS)) to 570 allow direct comparison. Only valid pairs of epochs between PSG and device are used for the 571 concordance analysis. The analysis window is set as the total recording period (~10 hours). The EBE concordance metrics for the devices are estimated from the confusion matrices 572 573 constructed. The concordance metrics used for the analysis of all the different sleep stage 574 levels include, sensitivity, specificity, accuracy, Matthew's correlation coefficient (MCC) and 575 F1 score. Similar to the sleep summary measures analysis, an agreement matrix for EBE 576 concordance is created using MCC. MCC is preferred to other concordance metrics since it 577 accounts for class imbalance commonly encountered in hypnogram data and is a better 578 alternative to the metrics such as kappa or its variants [73]. The final device ranking is 579 created using the summary sleep measures and EBE agreement matrix. Furthermore, the 580 effect of participant characteristics such as age, sex, BMI, AHI and other confounding factors 581 on the device accuracy and reliability are also explored.

582

583 Environmental measures

584 Characterising the environment, in particular light, is crucial to understanding

585 sleep/circadian physiology in the real-world and in different disease states. In the current

586 studies, light exposure patterns were assessed by both static and worn devices which

587	recorded lux values at one-minute intervals. One wearable (which measures white, red,
588	green and blue light) was worn on the wrist and one was clipped on clothing near the
589	collarbone; the static device was placed in the room of the home where the participant
590	spent the majority of their time. During data visualisation, imputation was performed for
591	any periods during which the participants were awake, but the measured light levels were 0
592	lux, which could be due to the sensors being accidentally covered. The imputation consisted
593	of replacing these zero values with the median value from the preceding and succeeding 30
594	min. This was calculated across all available days of data for each participant separately.
595	The consistency of measurements between devices was assessed by performing correlations
596	between the lux values obtained by the wrist worn and collarbone-worn devices.
597	
598	Quality assurance and mitigating issues Troubleshooting
599	To maximise data completeness and quality, during the study conduct, data acquisition from
599 600	To maximise data completeness and quality, during the study conduct, data acquisition from wi-fi enabled devices is monitored daily and participants can be contacted if any issues arise.
599 600 601	To maximise data completeness and quality, during the study conduct, data acquisition from wi-fi enabled devices is monitored daily and participants can be contacted if any issues arise. Participants are also able to contact the researchers 24/7 with any issues or concerns. Some
599 600 601 602	To maximise data completeness and quality, during the study conduct, data acquisition from wi-fi enabled devices is monitored daily and participants can be contacted if any issues arise. Participants are also able to contact the researchers 24/7 with any issues or concerns. Some potential issues that may arise and their mitigations are presented in Table 2.
599 600 601 602 603	To maximise data completeness and quality, during the study conduct, data acquisition from wi-fi enabled devices is monitored daily and participants can be contacted if any issues arise. Participants are also able to contact the researchers 24/7 with any issues or concerns. Some potential issues that may arise and their mitigations are presented in Table 2.
599 600 601 602 603 604	To maximise data completeness and quality, during the study conduct, data acquisition from wi-fi enabled devices is monitored daily and participants can be contacted if any issues arise. Participants are also able to contact the researchers 24/7 with any issues or concerns. Some potential issues that may arise and their mitigations are presented in Table 2.
599 600 601 602 603 604 605	To maximise data completeness and quality, during the study conduct, data acquisition from wi-fi enabled devices is monitored daily and participants can be contacted if any issues arise. Participants are also able to contact the researchers 24/7 with any issues or concerns. Some potential issues that may arise and their mitigations are presented in Table 2.
599 600 601 602 603 604 605 606	To maximise data completeness and quality, during the study conduct, data acquisition from wi-fi enabled devices is monitored daily and participants can be contacted if any issues arise. Participants are also able to contact the researchers 24/7 with any issues or concerns. Some potential issues that may arise and their mitigations are presented in Table 2.
599 600 601 602 603 604 605 606 607	To maximise data completeness and quality, during the study conduct, data acquisition from wi-fi enabled devices is monitored daily and participants can be contacted if any issues arise. Participants are also able to contact the researchers 24/7 with any issues or concerns. Some potential issues that may arise and their mitigations are presented in Table 2.
599 600 601 602 603 604 605 606 607 608	To maximise data completeness and quality, during the study conduct, data acquisition from wi-fi enabled devices is monitored daily and participants can be contacted if any issues arise. Participants are also able to contact the researchers 24/7 with any issues or concerns. Some potential issues that may arise and their mitigations are presented in Table 2.
 599 600 601 602 603 604 605 606 607 608 609 	To maximise data completeness and quality, during the study conduct, data acquisition from wi-fi enabled devices is monitored daily and participants can be contacted if any issues arise. Participants are also able to contact the researchers 24/7 with any issues or concerns. Some potential issues that may arise and their mitigations are presented in Table 2.

611	Table 2.	Device evaluation	studies: potential	issues and mitigations
-----	----------	-------------------	--------------------	------------------------

Potential issue	Mitigation
Device synchronization: Devices may not	Possible solutions could be using a
be time synchronized if they were	physiological signal e.g., eye blinks or
setup/downloaded/analysed on different	moving the wrist, as a synchronizing signal
systems. This could be due to the fact that	for cross correlation.
some devices will use timestamps on local	
machines whereas others use UTC. This	
has previously been identified as being	
critical for epoch-by-epoch analysis [47].	
Missing data: This could occur due to	Potential mitigations include: a) ensuring
equipment malfunction, user error, data	participants are thoroughly trained in the
signal loss, data storage insufficiency, or	use of all equipment and provide
user error (e.g., wearing the device	instructions to take home, b) where
incorrectly, not using the device when	possible, remotely monitor data acquisition
required, forgetting to update apps,	and follow up if needed, c) test all
forgetting to enter data, unplugging or	equipment before use.
obstructing nearable devices)	

612

- 613 Expertise needed to implement the protocol
- 614 These studies require a team of trained personnel to ensure participant safety and well-
- being as well as data quality and integrity including troubleshooting issues with devices.
- 616 This level of support is required from the point of consent, throughout the at-home data
- 617 collection and for the overnight laboratory session. In addition, specialised and competent
- 618 staff are required for collecting blood samples, PSG instrumentation, PSG recordings, PSG
- 619 scoring, and data analysis.

620

621 Results

622 Participant characterisation

- 623 For our initial protocol, 45 out of 46 cognitively intact participants were screened and
- 624 deemed eligible for the study and, of these, 36 participants were enrolled in the study and

625	35 participants (14 female: 21 male) completed the study. They had a mean age of 70.8 \pm
626	4.9 years (range: 65 – 83 years) and a mean BMI of 26.7 \pm 4.7 kg/m ² (range: 20 – 40) which
627	is representative of the UK population in this age bracket [74]. Current co-morbid stable
628	medical conditions were reported by 40% of participants, including type 2 diabetes,
629	arthritis, and hypertension, and 26% of participants were on prescribed medications. The
630	participants had the following scores (mean ± SD) from the baseline questionnaires: a) PSQI:
631	4.1 ± 2.1, b) ESS: 3.6 ± 2.5, c) ADL: 7.9 ± 0.2, d) ICIQ: 1.0 ± 1.7, e) S-MMSE: 28.7 ± 1.4. From
632	the laboratory session, it was identified that 89% of participants had apnoea-hypopnea
633	(AHI) scores indicative of sleep apnoea: 40% mild (AHI: 5 – 14), 26% moderate (AHI: 15 - 30)
634	and 23% severe (AHI: > 30).
635	For our feasibility study in PLWD and their study partners, to date we have enrolled
636	seven control participants (65 – 85 years) (3 females: 4 males) who had a mean age of 67.0 \pm
637	6.2 years (range 61 – 79 years) and a mean BMI of 26.4 \pm 3.8 kg/m ² (range: 22 – 32.6). We
638	have enrolled 11 PLWD of whom eight (4 females: 4 males) have completed the study and
639	six of these had study partners (3 females: 3 males). The PLWD had a mean age of 74.8 \pm
640	4.4 years (range 67 – 81 years) and a mean BMI of 29.7 \pm 7.6 kg/m ² (range: 20.7 – 42.1). The
641	study partners had a mean age of 66.7 \pm 14.8 years (range 44 – 80 years) and a mean BMI of
642	28.9 \pm 4.1 kg/m ² (range: 23.9 – 33.6). These participants also report stable co-morbid
643	medical conditions including type 2 diabetes, hypertension, arthritis and hypothyroidism,
644	and are taking concomitant medications.
645	

646 Data completeness

647 The 35 cognitively intact participants from our initial study collected data for 7-14 days at
648 home which combined was a total of 397 days/nights. We recorded from 6-10 devices

- 649 (number of nights per device depended upon participant and device) which was a total of
- 650 2748 device days/nights from all the devices combined and we had 95% data completeness.
- In the laboratory, we recorded 35 nights with 8-10 devices which was 331 device nights,
- 652 including PSG, and achieved 98% data completeness.
- 653

654 Device acceptability

- For all the wearable devices (n = 35 reported), participants rated the comfort as 3.8 ± 1.9
- and the ease of use as 6.0 ± 1.2 . For the nearable devices (n = 17 reported), participants
- rated the comfort as 6.3 ± 1.2 and the ease of use as 6.3 ± 1.1 .
- 658

659 Examples of at-home and in-laboratory recordings

660 One of the strengths of our approach and using multiple simultaneous devices is that it is

661 possible to obtain concurrent physiological, behavioural, and environmental signals both at-

- 662 home and in a laboratory setting. Here we show examples from individual participants of
- 663 the datasets that can be obtained.

664 Figure 5 shows exemplar data from a cognitively intact male participant in their 60s who had

- 665 moderate sleep apnoea (AHI = 24.1) and was living with controlled type 2 diabetes. The
- raster plot includes 14-consecutive days of home recording followed by the overnight in-
- 667 laboratory session, simultaneously using two contactless, nearable technologies and a wrist
- 668 worn actigraphy device (actigraphy was not used in the laboratory) with completion of a
- subjective sleep diary. The raster plot provides a measure of sleep behaviour and shows the
- 670 day-to-day variation in sleep timing. The two under-mattress, contactless devices
- accurately detect bed presence as demonstrated by their concordance with the information

dellaMonica C_et_al_Manuscript.docx

- 672 captured in the sleep diary [52]. These devices can also capture daytime naps taken in bed
- and generate automated sleep summaries (boxed regions in the raster).



Figure 5. Multiple days of at-home recording (days -14 to -1) and a single overnight laboratory session (day 0) in a male participant in their 60s. The grey bars represent when the participant is out of bed and the purple and green bars represent when the participant is in bed as detected by two different 'under the mattress' nearable devices (Nearable 1 and nearable 2, respectively). For Nearable 1, the light pink represents periods of wake, and the darker purple represents sleep; for Nearable 2, the light green represents periods of wake and the darker green represents sleep. The bed entry and bed exit times recorded on the

683 sleep diary are represented by inverted grey and pink triangles, respectively, and the black 684 triangle indicates estimated sleep onset according to the sleep diary. The horizontal 685 magenta lines represent nap times recorded on the sleep diary. The blue bars represent 686 wrist worn actigraphy with dark blue indicating sleep and light blue representing wake. 687 Figure 6 provides an example of data captured in the laboratory session where 688 polysomnography was recorded for 10 hours with simultaneous use of three nearable 689 devices. For each nearable, discrepancy between the device and manually scored PSG are 690 indicated with darker coloured bands at three different levels of sleep stage classification: 1) 691 wake vs sleep, 2) wake vs NREM vs REM, 3) wake vs deep sleep vs light sleep vs REM. For all three nearable devices it can be seen that as the resolution of the sleep staging increases so 692 693 do the number of discordant epochs. Thus, while the nearable devices might be able to 694 distinguish between wake and sleep, they cannot accurately distinguish between different 695 stages of sleep. 696 Figure 7 provides an example of heart rate and breathing rate captured from PSG and three 697 nearable devices from a single participant during a 10-hour period in bed in the laboratory. 698 The pattern observed in the vital signs with Nearable 1 matches that detected by the gold 699 standard PSG signals, whereas Nearable 2 records some spikes in heart rate that are not

seen in the PSG or Nearable 1. Nearable 3 only records breathing rate, and the signal is

701 consistent across the course of the night.



703 Figure 6. Hypnograms from a 10-hour in-bed period in a laboratory environment in a single 704 participant with simultaneous polysomnography, including video, and three nearable 705 devices. The black vertical dotted line depicts Lights Off and the red vertical dotted line 706 depicts Lights On. The orange horizontal bar represents bed occupancy according to the 707 video, with darker lines indicating when the participant left the bed. For each nearable, the 708 discrepancy between the nearable and the PSG determined sleep is depicted at three 709 different levels of sleep stage classification: 1) wake vs sleep, 2) wake vs NREM vs REM, 3) 710 wake vs deep sleep vs light sleep vs REM. The darker coloured region indicates epochs of 711 discrepancy. BO = bed occupancy, S = Sleep, W = wake, NR = NREM, NP = not present, REM 712 = rapid eye movement sleep, LS = light sleep, DS = deep sleep.



713

714 Figure 7. Physiological measures during a 10-hour in-bed period in a laboratory 715 environment in a single participant with simultaneous recordings of polysomnography, 716 including video, and from three nearable devices. The black vertical dotted line depicts 717 Lights Off and the red vertical dotted line depicts Lights On. The orange horizontal bar 718 represents bed occupancy according to the video, with darker lines indicating when the participant left the bed. For each nearable device, blue lines represent breathing rate and 719 720 red lines represent heart rate. Within the PSG hypnogram, BO = bed occupancy, A = 721 artefact, W = wake, R = REM sleep, N1 = stage 1 NREM sleep, N2 = stage 2 NREM sleep, N3 = 722 stage 3 NREM sleep.







725	Figure 8. Multiple days of at-home recording (days -14 to -1) and a single overnight
726	laboratory session (day 0) from a PLWD and their partner who share a bed. The grey bars
727	represent when the participant is out of bed and the purple and red bars represent when
728	the participant is in bed as detected by two different nearable devices (Nearable 1 and
729	Nearable 2, respectively). The purple bars represent an under-mattress sensor and the red
730	bars a bedside sensor; for both, the darker shading indicates sleep and the light shading
731	indicates wake. The bed entry and bed exit times recorded on the sleep diary are
732	represented by inverted grey and pink triangles, respectively, and the black triangle
733	indicates estimated sleep onset according to the sleep diary.
734	Figure 8 shows multiple consecutive days of recording in a woman living with dementia in
735	her 70s and her partner, a man in his 80s, who share a bed. The PLWD's sleep is fragmented
736	and varies from day to day in terms of duration and timing. The partner also experiences
737	nights of discontinuous sleep.
738	Figure 9 is an example of light exposure data for a 24-hour period for an individual from two
739	worn devices, as well as the light levels in the room in their house in which they spend the

majority of their time. For the 17 participants who wore both the actiwatch and HOBO, the was a significant correlation between the measured values by the two devices (r = 0.36, p < 0.001). For this individual, their morning light exposure is up to 10,000 lux and exceeds the light levels in their home, suggesting they are outside. Their afternoon light exposure varies between 10 and 1000 lux but is generally lower than the light levels measured in their house suggesting they are indoors. Their evening light exposure is quite low and generally \leq 100 lux.





748

Figure 9. Light exposure data (plotted on a Log scale) measured over a 24-hour period for one participant using three devices: a wrist-worn wearable (blue), a collarbone/lapel worn wearable (green), and a static room device (black) (where the participant spends the majority of their time). Grey shaded areas indicate sleep periods reported in the sleep diary, the vertical red dashed line is sunset, and the vertical pink dashed line is sunrise.

755 Discussion

756 We have described our successful approach for evaluating multiple, concurrent sleep/circadian monitoring technologies both at home and in the lab against accepted 757 758 standard measures in older people and PLWD. This approach is rather different from 759 published approaches in terms of the population enrolled, the number of devices evaluated 760 simultaneously in one individual, the use of home and lab assessments, and the analysis 761 interval used. Our high level of data completeness (95-98%) and participant retention (97%) 762 is an indication of the success of our approach. 763 The majority of previous evaluation studies have taken the approach of either 764 validating a single device against gold-standard or assessing multiple devices but not 765 simultaneously in the same individual. For example, Chinoy and colleagues took a similar 766 approach to us in simultaneously comparing seven consumer sleep tracking devices 767 (wearable and contactless) in young participants at home and in the laboratory but 768 participants only used a subset of the devices [48]. A strength of our design is that 769 participants utilised multiple devices simultaneous to maximise evaluations and 770 comparisons. 771 The predominant inclusion of young and healthy individuals in device evaluation studies 772 limits the applications of the findings [48, 75-77]. In addition, only evaluating the 773 performance of a device using self-selected lights off/on period when sleep efficiency is high 774 means it is not possible to evaluate the ability of the device to discriminate quiet wake (e.g., 775 [75, 76]. Indeed, in a young healthy population, it was demonstrated that the performance 776 of both wearable and contactless devices worsened on a night of sleep disruption compared

to an undisturbed night in the laboratory [48].

dellaMonica C_et_al_Manuscript.docx

778 The value of assessing the device in the population in which it will be used was 779 highlighted by three recent studies. An assessment of the EMFIT-QS mattress sensor in 780 participants from a sleep disorders centre with a BMI of 33.8 ± 8.3 kg/m2 (mean ± SD; range 781 21.4 - 46.6) revealed that this device overestimated TST and underestimated WASO [78]. 782 However, the authors noted that the performance actually worsened in those with a high 783 apnoea-hypopnea index (AHI) and more fragmented sleep, but that estimations of TST 784 actually improved in participants with increased weight and BMI suggesting that the device 785 performs better with bigger movements from heavier individuals [78]. The Withings Sleep 786 Mattress Analyser was assessed in participants with suspected sleep apnoea, and the device 787 similarly overestimated sleep and underestimated wake but could accurately detect 788 moderate to severe sleep approve (AHI was 31.2 ± 25 and 32.8 ± 29.9 with PSG and WSA, 789 respectively) highlighting its diagnostic and monitoring value [79]. Finally, 293 cognitively 790 normal and mildly impaired older adults were monitored for up to six nights at home using 791 single channel EEG (scEEG), actigraphy and sleep diaries [80]. Estimates of TST showed the 792 greatest agreement across the methods, particularly for cognitively intact adults, but the 793 agreement between actigraphy and scEEG decreased in those with mild cognitive 794 impairment and biomarker evidence of Alzheimer's Disease. Thus, it is crucial that the 795 device is evaluated in a relevant population for its intended use. 796 The devices we are testing do have potential for long-term use in the home environment. The Withings Sleep Analyser has been deployed in PLWD where variation in 797 798 in night-time behaviour and physiology was shown to relate to disease progression, 799 comorbid illnesses and changes in medication [81]. 800 The approach we describe here could be applied to evaluate the performance and

801 acceptability of any novel sleep or circadian monitoring device in any population. To best

802 assess the device, it should be considered how the device would be used in the real-world 803 and what information is most relevant e.g., bed occupancy, sleep structure, distribution of 804 activity, light exposure. Our experimental design highlights the value of taking a multi-805 modal approach and assessing the performance of devices longitudinally at-home. 806 Combining information from multiple devices can assist with interpreting sleep-wake 807 behaviour as well as allowing their performance to be cross-validated. For example, the AWS provides information about activity levels but not about whether the participant is in 808 809 bed; however, when the AWS data is viewed in conjunction with the Withings Mattress data 810 it is possible to identify when the participant has left the bed rather than just being restless 811 in the bed. This is particularly relevant to PLWD whose nocturnal wandering is a major 812 reason for them to be moved from their home into a care home. 813 One challenge of the protocol was that many participants had not used smart 814 technology previously and we required participants to complete a number of procedures 815 independently which some PLWD were concerned about whether they would remember. 816 Thorough training sessions, provision of comprehensive written instructions, the role of the 817 study partner for PLWD, and frequent contact between researchers and participants 818 ensured that they felt supported and able to carry out all study procedures. 819 In conclusion, we have developed a novel protocol that allows multiple 820 sleep/circadian/environmental technologies to be assessed simultaneously in an individual 821 both at-home and in the laboratory. Our approach was successful in terms of data quality, 822 data completeness, and gaining an understanding of device acceptability. The protocol was 823 conducted in both cognitively intact older adults and PLWD to provide a comprehensive 824 picture of an individual's behaviour, physiology, and environment. 825

dellaMonica C et al Manuscript.docx

826 Acknowledgements

- 827 We thank Surrey Clinical Research Facility and Surrey and Borders Partnership Trust for
- 828 support with recruitment and residential sessions and Daniel Barrett, Marta Messina, and
- 829 Tegan Ward for their contribution to this work.
- 830

831 References

- 832
- 833 1. Patel SD, Davies A, Laing E, Wu H, Mendis J, Dijk DJ. Prognostication in Advanced
- 834 Cancer by Combining Actigraphy-Derived Rest-Activity and Sleep Parameters with Routine
- 835 Clinical Data: An Exploratory Machine Learning Study. Cancers (Basel). 2023;15(2). Epub
- 836 2023/01/22. doi: 10.3390/cancers15020503. PubMed PMID: 36672452; PubMed Central
- 837 PMCID: PMCPMC9856985.
- 838 2. Mander BA, Dave A, Lui KK, Sprecher KE, Berisha D, Chappel-Farley MG, et al.
- 839 Inflammation, tau pathology, and synaptic integrity associated with sleep spindles and
- 840 memory prior to beta-amyloid positivity. Sleep. 2022;45(9). Epub 2022/06/08. doi:
- 10.1093/sleep/zsac135. PubMed PMID: 35670275; PubMed Central PMCID:
- 842 PMCPMC9758508.

843 3. Meyer N, Harvey AG, Lockley SW, Dijk DJ. Circadian rhythms and disorders of the

- timing of sleep. Lancet. 2022;400(10357):1061-78. Epub 2022/09/18. doi: 10.1016/S0140-
- 845 6736(22)00877-7. PubMed PMID: 36115370.
- Murray JM, Sletten TL, Magee M, Gordon C, Lovato N, Bartlett DJ, et al. Prevalence
 of Circadian Misalignment and Its Association With Depressive Symptoms in Delayed Sleep

Phase Disorder. Sleep. 2017;40(1). Epub 2017/04/02. doi: 10.1093/sleep/zsw002. PubMed
PMID: 28364473.

5. Borbely AA. A two process model of sleep regulation. Hum Neurobiol. 1982;1(3):195-

851 204. Epub 1982/01/01. PubMed PMID: 7185792.

852 6. Dijk DJ, Czeisler CA. Paradoxical timing of the circadian rhythm of sleep propensity

853 serves to consolidate sleep and wakefulness in humans. Neurosci Lett. 1994;166(1):63-8.

Epub 1994/01/17. doi: 10.1016/0304-3940(94)90841-9. PubMed PMID: 8190360.

855 7. Dijk DJ, Czeisler CA. Contribution of the circadian pacemaker and the sleep

856 homeostat to sleep propensity, sleep structure, electroencephalographic slow waves, and

sleep spindle activity in humans. J Neurosci. 1995;15(5 Pt 1):3526-38. Epub 1995/05/01.

858 PubMed PMID: 7751928; PubMed Central PMCID: PMCPMC6578184.

859 8. Dijk DJ, von Schantz M. Timing and consolidation of human sleep, wakefulness, and

860 performance by a symphony of oscillators. J Biol Rhythms. 2005;20(4):279-90. Epub

861 2005/08/04. doi: 10.1177/0748730405278292. PubMed PMID: 16077148.

862 9. Duffy JF, Wright KP, Jr. Entrainment of the human circadian system by light. J Biol

863 Rhythms. 2005;20(4):326-38. Epub 2005/08/04. doi: 10.1177/0748730405277983. PubMed
864 PMID: 16077152.

865 10. Vandewalle G, Maquet P, Dijk DJ. Light as a modulator of cognitive brain function.

866 Trends Cogn Sci. 2009;13(10):429-38. Epub 2009/09/15. doi: 10.1016/j.tics.2009.07.004.

867 PubMed PMID: 19748817.

868 11. Nedergaard M, Goldman SA. Glymphatic failure as a final common pathway to

dementia. Science. 2020;370(6512):50-6. doi: 10.1126/science.abb8739. PubMed PMID:

870 33004510; PubMed Central PMCID: PMCPMC8186542.

dellaMonica C_et_al_Manuscript.docx

871 12. Winsky-Sommerer R, de Oliveira P, Loomis S, Wafford K, Dijk DJ, Gilmour G.

- 872 Disturbances of sleep quality, timing and structure and their relationship with other
- 873 neuropsychiatric symptoms in Alzheimer's disease and schizophrenia: Insights from studies
- in patient populations and animal models. Neurosci Biobehav Rev. 2019;97:112-37. Epub
- 875 20181009. doi: 10.1016/j.neubiorev.2018.09.027. PubMed PMID: 30312626.
- 876 13. Wang C, Holtzman DM. Bidirectional relationship between sleep and Alzheimer's
- disease: role of amyloid, tau, and other factors. Neuropsychopharmacology. 2020;45(1):104-
- 878 20. Epub 20190813. doi: 10.1038/s41386-019-0478-5. PubMed PMID: 31408876; PubMed
- 879 Central PMCID: PMCPMC6879647.
- 880 14. Andre C, Champetier P, Rehel S, Kuhn E, Touron E, Ourry V, et al. Rapid Eye
- 881 Movement Sleep, Neurodegeneration, and Amyloid Deposition in Aging. Ann Neurol.
- 882 2023;93(5):979-90. Epub 2023/01/16. doi: 10.1002/ana.26604. PubMed PMID: 36641644.
- 883 15. Sani TP, Bond RL, Marshall CR, Hardy CJD, Russell LL, Moore KM, et al. Sleep
- symptoms in syndromes of frontotemporal dementia and Alzheimer's disease: A proof-of-

principle behavioural study. eNeurologicalSci. 2019;17:100212. Epub 2019/12/13. doi:

886 10.1016/j.ensci.2019.100212. PubMed PMID: 31828228; PubMed Central PMCID:

887 PMCPMC6889070.

888 16. Seda G, Matwiyoff G, Parrish JS. Effects of Obstructive Sleep Apnea and CPAP on

889 Cognitive Function. Curr Neurol Neurosci Rep. 2021;21(7):32. Epub 2021/05/07. doi:

890 10.1007/s11910-021-01123-0. PubMed PMID: 33956247.

17. Aini N, Chu H, Banda KJ, Chen R, Lee TY, Pien LC, et al. Prevalence of sleep-related

892 breathing disorders and associated risk factors among people with dementia: A meta-

analysis. Sleep Med. 2023;103:51-61. Epub 2023/02/10. doi: 10.1016/j.sleep.2023.01.020.

894 PubMed PMID: 36758347.

18. Lin YQ, Chen SD. RBD: a red flag for cognitive impairment in Parkinson's disease?
Sleep Med. 2018;44:38-44. Epub 2018/03/14. doi: 10.1016/j.sleep.2018.01.006. PubMed
PMID: 29530367.

19. Liu Y, Song Y, Johnson FU, Lei L, Choi SE, Antonucci TC, et al. Characteristics and

899 Predictors of Sleep Among Spousal Care Dyads Living With Chronic Conditions. J Gerontol B

900 Psychol Sci Soc Sci. 2023;78(Suppl 1):S38-S47. Epub 2022/09/17. doi:

901 10.1093/geronb/gbac096. PubMed PMID: 36112385; PubMed Central PMCID:

902 PMCPMC10010479.

903 20. Van Hout E, Contreras M, Mioshi E, Kishita N. Examining the Impact of Different

904 Components of Sleep Quality on Anxiety Among Family Carers of People with Dementia. J

905 Geriatr Psychiatry Neurol. 2023;36(1):63-72. Epub 2022/04/20. doi:

906 10.1177/08919887221093359. PubMed PMID: 35437043; PubMed Central PMCID:

907 PMCPMC9755697.

908 21. Kim J, Cha E. Effect of Perceived Stress on Health-Related Quality of Life among

909 Primary Caregiving Spouses of Patients with Severe Dementia: The Mediating Role of

910 Depression and Sleep Quality. Int J Environ Res Public Health. 2022;19(13). Epub

911 2022/07/10. doi: 10.3390/ijerph19137962. PubMed PMID: 35805619; PubMed Central

912 PMCID: PMCPMC9265387.

913 22. Benca R, Herring WJ, Khandker R, Qureshi ZP. Burden of Insomnia and Sleep

914 Disturbances and the Impact of Sleep Treatments in Patients with Probable or Possible

Alzheimer's Disease: A Structured Literature Review. J Alzheimers Dis. 2022;86(1):83-109.

916 Epub 2022/01/11. doi: 10.3233/JAD-215324. PubMed PMID: 35001893; PubMed Central

917 PMCID: PMCPMC9028660.

dellaMonica C_et_al_Manuscript.docx

918 23. Gibson RH, Gander PH, Jones LM. Understanding the sleep problems of people with

dementia and their family caregivers. Dementia (London). 2014;13(3):350-65. Epub

920 2013/12/18. doi: 10.1177/1471301212473884. PubMed PMID: 24339061.

921 24. Lee DR, Thomas AJ. Sleep in dementia and caregiving--assessment and treatment

922 implications: a review. Int Psychogeriatr. 2011;23(2):190-201. Epub 2010/10/16. doi:

923 10.1017/S1041610210001894. PubMed PMID: 20946702.

924 25. Gibson AA, Gale J, Stamatakis E, Lindley RI, Fontana L, Cistulli PA, et al. Impact of

925 lifestyle risk factors on admission to nursing home care: a cohort study of 127 108 people

aged 60 years and over. J Epidemiol Community Health. 2023. Epub 2023/08/25. doi:

- 927 10.1136/jech-2023-220518. PubMed PMID: 37620005.
- 928 26. Wong ATY, Reeves GK, Floud S. Total sleep duration and daytime napping in relation

929 to dementia detection risk: Results from the Million Women Study. Alzheimers Dement.

930 2023. Epub 2023/04/21. doi: 10.1002/alz.13009. PubMed PMID: 37083147.

931 27. Balouch S, Dijk DAD, Rusted J, Skene SS, Tabet N, Dijk DJ. Night-to-night variation in

932 sleep associates with day-to-day variation in vigilance, cognition, memory, and behavioral

933 problems in Alzheimer's disease. Alzheimers Dement (Amst). 2022;14(1):e12303. Epub

934 2022/05/24. doi: 10.1002/dad2.12303. PubMed PMID: 35603140; PubMed Central PMCID:

935 PMCPMC9109375.

936 28. Berry R, BR GC, Harding S, Lloyd R, Marcus C, Vaughn B. The AASM Manual for the

937 Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications. The
938 Americal Academy of Sleep Medicine. 2016.

939 29. Dijk DJ, Duffy JF. Novel Approaches for Assessing Circadian Rhythmicity in Humans: A
940 Review. J Biol Rhythms. 2020;35(5):421-38. Epub 2020/07/24. doi:

dellaMonica C_et_al_Manuscript.docx

941 10.1177/0748730420940483. PubMed PMID: 32700634; PubMed Central PMCID:

942 PMCPMC7543025.

30. Sletten TL, Vincenzi S, Redman JR, Lockley SW, Rajaratnam SM. Timing of sleep and
its relationship with the endogenous melatonin rhythm. Front Neurol. 2010;1:137. Epub
2010/12/29. doi: 10.3389/fneur.2010.00137. PubMed PMID: 21188265; PubMed Central
PMCID: PMCPMC3008942.

947 31. Burgess HJ, Wyatt JK, Park M, Fogg LF. Home Circadian Phase Assessments with

948 Measures of Compliance Yield Accurate Dim Light Melatonin Onsets. Sleep. 2015;38(6):889-

949 97. Epub 2014/11/20. doi: 10.5665/sleep.4734. PubMed PMID: 25409110; PubMed Central

950 PMCID: PMCPMC4434555.

951 32. Lockley SW, Skene DJ, Arendt J, Tabandeh H, Bird AC, Defrance R. Relationship

952 between melatonin rhythms and visual loss in the blind. J Clin Endocrinol Metab.

953 1997;82(11):3763-70. Epub 1997/11/14. doi: 10.1210/jcem.82.11.4355. PubMed PMID:

954 9360538.

955 33. Lockley SW, Skene DJ, James K, Thapan K, Wright J, Arendt J. Melatonin

administration can entrain the free-running circadian system of blind subjects. J Endocrinol.

957 2000;164(1):R1-6. Epub 1999/12/23. doi: 10.1677/joe.0.164r001. PubMed PMID: 10607943.

958 34. Wulff K, Dijk DJ, Middleton B, Foster RG, Joyce EM. Sleep and circadian rhythm

disruption in schizophrenia. Br J Psychiatry. 2012;200(4):308-16. Epub 2011/12/24. doi:

960 10.1192/bjp.bp.111.096321. PubMed PMID: 22194182; PubMed Central PMCID:

961 PMCPMC3317037.

962 35. Stone JE, McGlashan EM, Quin N, Skinner K, Stephenson JJ, Cain SW, et al. The Role

963 of Light Sensitivity and Intrinsic Circadian Period in Predicting Individual Circadian Timing. J

964 Biol Rhythms. 2020:748730420962598. Epub 2020/10/17. doi: 10.1177/0748730420962598.

965 PubMed PMID: 33063595.

- 966 36. Skeldon AC, Dijk DJ, Meyer N, Wulff K. Extracting Circadian and Sleep Parameters
- 967 from Longitudinal Data in Schizophrenia for the Design of Pragmatic Light Interventions.
- 968 Schizophr Bull. 2022;48(2):447-56. Epub 2021/11/11. doi: 10.1093/schbul/sbab124.
- 969 PubMed PMID: 34757401; PubMed Central PMCID: PMCPMC8886588.
- 970 37. Menczel Schrire Z, Gordon CJ, Palmer JR, Murray J, Hickie I, Rogers NL, et al.
- 971 Actigraphic and melatonin alignment in older adults with varying dementia risk. Chronobiol
- 972 Int. 2023;40(2):91-102. Epub 2022/11/22. doi: 10.1080/07420528.2022.2144744. PubMed
- 973 PMID: 36408793.
- 38. Li J, Vitiello MV, Gooneratne NS. Sleep in Normal Aging. Sleep Med Clin.
- 975 2018;13(1):1-11. Epub 20171121. doi: 10.1016/j.jsmc.2017.09.001. PubMed PMID:
- 976 29412976; PubMed Central PMCID: PMCPMC5841578.
- 977 39. Mander BA, Winer JR, Walker MP. Sleep and Human Aging. Neuron. 2017;94(1):19-

978 36. doi: 10.1016/j.neuron.2017.02.004. PubMed PMID: 28384471; PubMed Central PMCID:

979 PMCPMC5810920.

- 980 40. Kent BA, Casciola AA, Carlucci SK, Chen M, Stager S, Mirian MS, et al. Home EEG
- 981 sleep assessment shows reduced slow-wave sleep in mild-moderate Alzheimer's disease.

982 Alzheimers Dement (N Y). 2022;8(1):e12347. Epub 2022/08/23. doi: 10.1002/trc2.12347.

- 983 PubMed PMID: 35992215; PubMed Central PMCID: PMCPMC9381912.
- 984 41. Casagrande M, Forte G, Favieri F, Corbo I. Sleep Quality and Aging: A Systematic
- 985 Review on Healthy Older People, Mild Cognitive Impairment and Alzheimer's Disease. Int J
- 986 Environ Res Public Health. 2022;19(14). Epub 2022/07/28. doi: 10.3390/ijerph19148457.
- 987 PubMed PMID: 35886309; PubMed Central PMCID: PMCPMC9325170.

988 42. de Zambotti M, Menghini L, Grandner MA, Redline S, Zhang Y, Wallace ML, et al.

- 989 Rigorous performance evaluation (previously, "validation") for informed use of new
- technologies for sleep health measurement. Sleep Health. 2022;8(3):263-9. Epub
- 991 2022/05/07. doi: 10.1016/j.sleh.2022.02.006. PubMed PMID: 35513978; PubMed Central
- 992 PMCID: PMCPMC9338437.
- 993 43. Green SF, Frame T, Banerjee LV, Gimson A, Blackman J, Morrison H, et al. A
- 994 systematic review of the validity of non-invasive sleep-measuring devices in mid-to-late life
- adults: Future utility for Alzheimer's disease research. Sleep Med Rev. 2022;65:101665.
- 996 Epub 2022/10/09. doi: 10.1016/j.smrv.2022.101665. PubMed PMID: 36208588.
- 997 44. Duffy JF, Zitting KM, Chinoy ED. Aging and Circadian Rhythms. Sleep Med Clin.
- 998 2015;10(4):423-34. Epub 2015/11/17. doi: 10.1016/j.jsmc.2015.08.002. PubMed PMID:
- 999 26568120; PubMed Central PMCID: PMCPMC4648699.
- 1000 45. Charman WN. Age, lens transmittance, and the possible effects of light on melatonin
- 1001 suppression. Ophthalmic Physiol Opt. 2003;23(2):181-7. Epub 2003/03/19. doi:
- 1002 10.1046/j.1475-1313.2003.00105.x. PubMed PMID: 12641706.
- 1003 46. Ancoli-Israel S, Klauber MR, Jones DW, Kripke DF, Martin J, Mason W, et al.
- 1004 Variations in circadian rhythms of activity, sleep, and light exposure related to dementia in
- 1005 nursing-home patients. Sleep. 1997;20(1):18-23. Epub 1997/01/01. PubMed PMID:
- 1006 9130329.
- 1007 47. Depner CM, Cheng PC, Devine JK, Khosla S, de Zambotti M, Robillard R, et al.
- 1008 Wearable technologies for developing sleep and circadian biomarkers: a summary of
- 1009 workshop discussions. Sleep. 2020;43(2). doi: 10.1093/sleep/zsz254. PubMed PMID:
- 1010 31641776; PubMed Central PMCID: PMCPMC7368340.

dellaMonica C_et_al_Manuscript.docx

1011 48. Chinoy ED, Cuellar JA, Huwa KE, Jameson JT, Watson CH, Bessman SC, et al.

1012 Performance of seven consumer sleep-tracking devices compared with polysomnography.

1013 Sleep. 2021;44(5). doi: 10.1093/sleep/zsaa291. PubMed PMID: 33378539; PubMed Central

- 1014 PMCID: PMCPMC8120339.
- 1015 49. Marino M, Li Y, Rueschman MN, Winkelman JW, Ellenbogen JM, Solet JM, et al.
- 1016 Measuring sleep: accuracy, sensitivity, and specificity of wrist actigraphy compared to

1017 polysomnography. Sleep. 2013;36(11):1747-55. Epub 20131101. doi: 10.5665/sleep.3142.

1018 PubMed PMID: 24179309; PubMed Central PMCID: PMCPMC3792393.

1019 50. Smith MT, McCrae CS, Cheung J, Martin JL, Harrod CG, Heald JL, et al. Use of

1020 Actigraphy for the Evaluation of Sleep Disorders and Circadian Rhythm Sleep-Wake

1021 Disorders: An American Academy of Sleep Medicine Systematic Review, Meta-Analysis, and

1022 GRADE Assessment. J Clin Sleep Med. 2018;14(7):1209-30. Epub 20180715. doi:

1023 10.5664/jcsm.7228. PubMed PMID: 29991438; PubMed Central PMCID: PMCPMC6040804.

1024 51. Ravindran GKK, della Monica C, Atzori G, Lambert D, Hassanin H, Revell V, et al.

1025 Three Contactless Sleep Technologies Compared to Actigraphy and Polysomnography in a

1026 Heterogenous Group of Older Men and Women in a Model of Mild Sleep Disturbance: A

1027 Sleep Laboratory Study. JMIR mHealth and uHealth. 2023;25/08/2023:46338 -

1028 (forthcoming/in press).

1029 52. Ravindran KKG, della Monica C, Atzori G, Lambert D, Hassanin H, Revell V, et al.

1030 Contactless and Longitudinal Monitoring of Nocturnal Sleep and Daytime Naps in Older Men

and Women: A Digital Health Technology Evaluation Study. Sleep. 2023. Epub 2023/07/20.

1032 doi: 10.1093/sleep/zsad194. PubMed PMID: 37471049.

dellaMonica C_et_al_Manuscript.docx

1033 53. Molloy DW, Standish TI. A guide to the standardized Mini-Mental State Examination.

1034 Int Psychogeriatr. 1997;9 Suppl 1:87-94; discussion 143-50. Epub 1997/01/01. doi:

1035 10.1017/s1041610297004754. PubMed PMID: 9447431.

1036 54. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness

1037 scale. Sleep. 1991;14(6):540-5. Epub 1991/12/01. doi: 10.1093/sleep/14.6.540. PubMed

1038 PMID: 1798888.

1039 55. Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep

1040 Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res.

1041 1989;28(2):193-213. Epub 1989/05/01. doi: 10.1016/0165-1781(89)90047-4. PubMed PMID:

1042 2748771.

1043 56. Lawton MP, Brody EM. Assessment of older people: self-maintaining and

1044 instrumental activities of daily living. Gerontologist. 1969;9(3):179-86. Epub 1969/01/01.

1045 PubMed PMID: 5349366.

1046 57. Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P. ICIQ: a brief and robust

1047 measure for evaluating the symptoms and impact of urinary incontinence. Neurourol

1048 Urodyn. 2004;23(4):322-30. Epub 2004/07/01. doi: 10.1002/nau.20041. PubMed PMID:

1049 15227649.

1050 58. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr

1051 Scand. 1983;67(6):361-70. Epub 1983/06/01. doi: 10.1111/j.1600-0447.1983.tb09716.x.

1052 PubMed PMID: 6880820.

1053 59. Logsdon RG, Gibbons LE, McCurry SM, Teri L. Assessing quality of life in older adults

1054 with cognitive impairment. Psychosom Med. 2002;64(3):510-9. Epub 2002/05/22. doi:

1055 10.1097/00006842-200205000-00016. PubMed PMID: 12021425.

dellaMonica C_et_al_Manuscript.docx

1056 60. Nelson H, Willison J. National adult reading test (NART) manual. Windsor, Bershire,

1057 UK: NFER-Nelson. 1982.

1058 61. Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin Questionnaire

to identify patients at risk for the sleep apnea syndrome. Ann Intern Med. 1999;131(7):485-

1060 91. Epub 1999/10/03. doi: 10.7326/0003-4819-131-7-199910050-00002. PubMed PMID:

1061 10507956.

1062 62. Horne JA, Ostberg O. A self-assessment questionnaire to determine morningness-

1063 eveningness in human circadian rhythms. Int J Chronobiol. 1976;4(2):97-110. Epub

1064 1976/01/01. PubMed PMID: 1027738.

1065 63. Berry RB, Wagner MH. Sleep medicine pearls Elsevier Health Sciences; 2015.

1066 64. Carney CE, Buysse DJ, Ancoli-Israel S, Edinger JD, Krystal AD, Lichstein KL, et al. The

1067 consensus sleep diary: standardizing prospective sleep self-monitoring. Sleep.

1068 2012;35(2):287-302.

1069 65. Bannon A, Rapeaux A, Constandinou TG. Tiresias: A low-cost networked UWB radar

1070 system for in-home monitoring of dementia patients. Annu Int Conf IEEE Eng Med Biol Soc.

1071 2021;2021:7068-72. Epub 2021/12/12. doi: 10.1109/EMBC46164.2021.9630533. PubMed

1072 PMID: 34892730.

1073 66. Malek-Ahmadi M, Su Y, Ghisays V, Luo J, Devadas V, Chen Y, et al. Plasma NfL is

1074 associated with the APOE epsilon4 allele, brain imaging measurements of

1075 neurodegeneration, and lower recall memory scores in cognitively unimpaired late-middle-

aged and older adults. Alzheimers Res Ther. 2023;15(1):74. Epub 2023/04/11. doi:

1077 10.1186/s13195-023-01221-w. PubMed PMID: 37038190; PubMed Central PMCID:

1078 PMC10084600.

dellaMonica C_et_al_Manuscript.docx

1079 67. Mattsson-Carlgren N, Salvado G, Ashton NJ, Tideman P, Stomrud E, Zetterberg H, et

- 1080 al. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma
- 1081 Biomarkers. JAMA Neurol. 2023;80(4):360-9. Epub 2023/02/07. doi:
- 1082 10.1001/jamaneurol.2022.5272. PubMed PMID: 36745413.
- 1083 68. Blennow K, Galasko D, Perneczky R, Quevenco FC, van der Flier WM, Akinwonmi A,
- 1084 et al. The potential clinical value of plasma biomarkers in Alzheimer's disease. Alzheimers
- 1085 Dement. 2023. Epub 2023/09/11. doi: 10.1002/alz.13455. PubMed PMID: 37694991.
- 1086 69. Ding L, Chen B, Dai Y, Li Y. A meta-analysis of the first-night effect in healthy
- 1087 individuals for the full age spectrum. Sleep Med. 2022;89:159-65. Epub 2022/01/09. doi:
- 1088 10.1016/j.sleep.2021.12.007. PubMed PMID: 34998093.
- 1089 70. Martin JL, Hakim AD. Wrist actigraphy. Chest. 2011;139(6):1514-27. Epub
- 1090 2011/06/10. doi: 10.1378/chest.10-1872. PubMed PMID: 21652563; PubMed Central
- 1091 PMCID: PMCPMC3109647.
- 1092 71. Menghini L, Cellini N, Goldstone A, Baker FC, de Zambotti M. A standardized
- 1093 framework for testing the performance of sleep-tracking technology: step-by-step
- 1094 guidelines and open-source code. Sleep. 2021;44(2). Epub 2020/09/04. doi:
- 1095 10.1093/sleep/zsaa170. PubMed PMID: 32882005; PubMed Central PMCID:
- 1096 PMCPMC7879416.
- 1097 72. Haghayegh S, Kang HA, Khoshnevis S, Smolensky MH, Diller KR. A comprehensive
- 1098 guideline for Bland-Altman and intra class correlation calculations to properly compare two
- 1099 methods of measurement and interpret findings. Physiol Meas. 2020;41(5):055012. Epub
- 1100 2020/04/07. doi: 10.1088/1361-6579/ab86d6. PubMed PMID: 32252039.

dellaMonica C_et_al_Manuscript.docx

- 1101 73. Chicco D, Warrens MJ, Jurman G. The Matthews Correlation Coefficient (MCC) is
- 1102 More Informative Than Cohen's Kappa and Brier Score in Binary Classification Assessment.
- 1103 IEEE Access. 2021;9:78368-81. doi: 10.1109/ACCESS.2021.3084050.
- 1104 74. Digital N. Mean body mass index (BMI) of adults in England 2021, by gender and age
- 1105 (in kilograms per meters squared) [Graph].
- 1106 https://www.statista.com/statistics/375886/adult-s-body-mass-index-by-gender-and-age-
- 1107 <u>in-england/2022</u>.
- 1108 75. Arnal PJ, Thorey V, Debellemaniere E, Ballard ME, Bou Hernandez A, Guillot A, et al.
- 1109 The Dreem Headband compared to polysomnography for electroencephalographic signal
- acquisition and sleep staging. Sleep. 2020;43(11). Epub 2020/05/21. doi:
- 1111 10.1093/sleep/zsaa097. PubMed PMID: 32433768; PubMed Central PMCID:
- 1112 PMCPMC7751170.
- 1113 76. Toften S, Pallesen S, Hrozanova M, Moen F, Gronli J. Validation of sleep stage
- 1114 classification using non-contact radar technology and machine learning (Somnofy(R)). Sleep

1115 Med. 2020;75:54-61. Epub 2020/08/28. doi: 10.1016/j.sleep.2020.02.022. PubMed PMID:

1116 32853919.

1117 77. Chinoy ED, Cuellar JA, Jameson JT, Markwald RR. Performance of Four Commercial

1118 Wearable Sleep-Tracking Devices Tested Under Unrestricted Conditions at Home in Healthy

1119 Young Adults. Nat Sci Sleep. 2022;14:493-516. Epub 20220322. doi: 10.2147/NSS.S348795.

- 1120 PubMed PMID: 35345630; PubMed Central PMCID: PMCPMC8957400.
- 1121 78. Kholghi M, Szollosi I, Hollamby M, Bradford D, Zhang Q. A validation study of a
- 1122 ballistocardiograph sleep tracker against polysomnography. J Clin Sleep Med.
- 1123 2022;18(4):1203-10. Epub 2021/10/28. doi: 10.5664/jcsm.9754. PubMed PMID: 34705630;
- 1124 PubMed Central PMCID: PMCPMC8974370.

1125	70	Edouard D	Compo D	Partot D	Vang DV	Bruynool M	Poismon G	ot al Validation o	f
1122	79.	Euouaru P	, Campo D	Dariel P	, tang kt	, bruyneer w	, RUISIIIAII G	, et al. valluation o	4

- the Withings Sleep Analyzer, an under-the-mattress device for the detection of moderate-
- 1127 severe sleep apnea syndrome. J Clin Sleep Med. 2021;17(6):1217-27. Epub 2021/02/17. doi:
- 1128 10.5664/jcsm.9168. PubMed PMID: 33590821; PubMed Central PMCID: PMCPMC8314651.
- 1129 80. Chou CA, Toedebusch CD, Redrick T, Freund D, McLeland JS, Morris JC, et al.
- 1130 Comparison of single-channel EEG, actigraphy, and sleep diary in cognitively normal and
- 1131 mildly impaired older adults. Sleep Adv. 2020;1(1):zpaa006. Epub 2021/03/02. doi:
- 1132 10.1093/sleepadvances/zpaa006. PubMed PMID: 33644758; PubMed Central PMCID:
- 1133 PMCPMC7898727.
- 1134 81. Soreq E, Kolanko MA, della Monica C, Ravindran KKG, Revell VL, de Villèle P, et al.
- 1135 Monitoring abnormal nocturnal behaviour in the homes of patients living with dementia.
- 1136 Alzheimer's & Dementia. 2022;18:e067936.
- 1137